Thoroughbred Financial Services LLC Takes $1.38 Million Position in Natera, Inc. (NASDAQ:NTRA)

Thoroughbred Financial Services LLC bought a new position in shares of Natera, Inc. (NASDAQ:NTRA) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 12,746 shares of the medical research company’s stock, valued at approximately $1,380,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Principal Securities Inc. acquired a new stake in shares of Natera during the fourth quarter worth about $32,000. GAMMA Investing LLC lifted its holdings in Natera by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after buying an additional 108 shares in the last quarter. YHB Investment Advisors Inc. purchased a new position in Natera in the 1st quarter valued at approximately $36,000. Tobam acquired a new position in shares of Natera in the second quarter worth $74,000. Finally, DekaBank Deutsche Girozentrale purchased a new stake in shares of Natera during the first quarter worth $83,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Stock Performance

Shares of NTRA stock opened at $126.51 on Friday. The stock’s 50-day moving average is $112.73 and its two-hundred day moving average is $103.78. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $128.28. The firm has a market cap of $15.65 billion, a price-to-earnings ratio of -40.55 and a beta of 1.53.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The firm had revenue of $413.35 million for the quarter, compared to the consensus estimate of $343.00 million. During the same quarter last year, the business posted ($0.97) EPS. The firm’s quarterly revenue was up 58.1% compared to the same quarter last year. Analysts predict that Natera, Inc. will post -1.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Canaccord Genuity Group boosted their target price on Natera from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, August 27th. TD Cowen boosted their price objective on Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Stephens reaffirmed an “overweight” rating and issued a $125.00 target price on shares of Natera in a report on Friday, August 9th. Morgan Stanley boosted their price target on shares of Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. Finally, StockNews.com downgraded shares of Natera from a “hold” rating to a “sell” rating in a research report on Wednesday, August 28th. One analyst has rated the stock with a sell rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and a consensus price target of $120.07.

Insiders Place Their Bets

In related news, CEO Steven Leonard Chapman sold 6,105 shares of Natera stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $111.61, for a total value of $681,379.05. Following the sale, the chief executive officer now directly owns 213,351 shares in the company, valued at $23,812,105.11. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CEO Steven Leonard Chapman sold 6,105 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $111.61, for a total value of $681,379.05. Following the completion of the transaction, the chief executive officer now directly owns 213,351 shares of the company’s stock, valued at approximately $23,812,105.11. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jonathan Sheena sold 12,000 shares of the business’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $121.01, for a total transaction of $1,452,120.00. Following the completion of the sale, the insider now owns 287,441 shares in the company, valued at $34,783,235.41. The disclosure for this sale can be found here. In the last quarter, insiders sold 92,388 shares of company stock worth $10,205,064. 7.60% of the stock is owned by insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.